Skip to main content

Self-reliant bioactive forms of vitamin B12

Ref-Nr: TA-ZEE20170210


Kurzfassung

Vitamin B12 deficiency can originate due to poor nutrition or due to genetic mutations in genes that are essential for the utilization of this micronutrient in cells. Current chemical forms of vitamin B12 are unable to halt disease progression, i.e. neurological and hematological symptoms, in conditions that block this micronutrient utilization in humans. One case is the cblC genetic disease as well as other pathologies leading to B12-dependent homocystinuria and methylmalonic aciduria where B12 reaches the cells but it cannot be utilized. Herein, a new generation of B12 forms is presented, with the intrinsic property of bypassing intracellular enzymatic processing, undergoing self-activation in cells, and thus promising a superior therapeutic avenue for patients with the cblC disease and other forms of vitamin B12 deficiency. This new generation of B12 forms is expected to alleviate or correct vitamin B12 deficiencies associated with aging or with neurological impairments such as Alzheimer and Parkinson’s disease, where brain atrophy and cognitive decline are hallmarks.


Hintergrund

 

 


Lösung

Self-reliant bioactive forms of vitamin B12 that bypass intracellular enzymatic processing of the micronutrient


Anwendungsbereiche

  • Newborns with a gene defect in the cblC (MMACHC) gene and other vitamin B12-dependent disorders leading to:
    - homocystinuria
    - methylmalonic aciduria
  • Elderly people with latent, subclinical vitamin B12 deficiency
  • Supportive treatment of Alzheimer's and dementia patients
  • Vegetarians and vegans

Developmental Status

 

  • This new generation of self-reliant forms of vitamin B12 has been synthesized and isolated in pure form.
  • Chemical reactivity with physiological reductants exhibited self-reliant activation
  • The enzymatic activity of pathogenic variants of the cblC enzyme causing early and late disease onset in humans was restored to near normal levels
  • Homocystinuria and methylmalonic aciduria where corrected in cblC patient cells

Campus Technologies Freiburg GmbH

Dr. Claudia Skamel
+49 (0) 761/203 499
claudia.skamel@campus-technologies.de
www.campus-technologies.de
Adresse
Stefan-Meier-Str. 8
79104 Freiburg



Patentsituation

  • PCT anhängig
  • EP anhängig

Stichworte

Pharma; Dietary supplements

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr